About achieve life sciences - ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
ACHV At a Glance
Achieve Life Sciences, Inc.
1040 West Georgia Street
Vancouver, British Columbia V6E 4H1
| Phone | 1-604-210-2217 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -39,827,000.00 | |
| Sector | Health Technology | Employees | 25 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ACHV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.842 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.278 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.113 |
ACHV Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,593,080.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ACHV Liquidity
| Current Ratio | 5.457 |
| Quick Ratio | 5.457 |
| Cash Ratio | 5.142 |
ACHV Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -137.325 |
| Return on Equity | -409.511 |
| Return on Total Capital | -129.07 |
| Return on Invested Capital | -271.301 |
ACHV Capital Structure
| Total Debt to Total Equity | 47.648 |
| Total Debt to Total Capital | 32.271 |
| Total Debt to Total Assets | 25.776 |
| Long-Term Debt to Equity | 47.385 |
| Long-Term Debt to Total Capital | 32.093 |